GOTHENBURG, Sweden, April 18, 2024 /PRNewswire/ --
First quarter
- Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.
- Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas.
- Sales per business area, in local currencies was +12% in Consumables, +8% in Technologies and -12% in Genetics.
- Gross margin increased to 57.1% (56.8).
- Operating income before depreciation and amortisation (EBITDA) increased to SEK 272 (262) million, giving an EBITDA margin of 32.4% (30.6).
- Operating cash flow increased to SEK 198 million (160).
- Net income was SEK 115 (99) million, resulting in earnings per share of SEK 0.85 (0.74).
- The product area Genomics was previously reported in Consumables business area but is now part of Genetic Services business area, renamed to Genetics business area.
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 18-04-2024 08:00 CET.
Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q1--2024--strong-growth-in-apac-and-solid-margins,c3963367
The following files are available for download:
https://mb.cision.com/Main/1031/3963367/2740767.pdf | Interim report Q1, 2024 |
SOURCE Vitrolife AB (publ)
